Clinical trial
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
NCT00005872 · Astex Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00005872 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer |
| Official title | Phase II Study of RFS 2000 in Relapsed NSCLC |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Start date | May 1, 1999 |
| Completion | Apr 1, 2004 |
| First posted | Apr 12, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: